Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept

被引：7

作者：

Otten, Marieke H. ^{[1
]}

Prince, Femke H. M. ^{[1
]}

Twilt, Marinka ^{[2
]}

van Rossum, Marion A. J. ^{[3
]}

Armbrust, Wineke ^{[4
]}

Hoppenreijs, Esther P. A. H. ^{[5
]}

Kamphuis, Sylvia ^{[1
]}

Koopman-Keemink, Yvonne ^{[6
]}

Wulffraat, Nico M. ^{[7
]}

Gorter, Simone L. ^{[8
]}

ten Cate, Rebecca ^{[2
]}

van Suijlekom-Smit, Lisette W. A. ^{[1
]}

机构：

[1] Erasmus MC, Sophia Childrens Hosp, Dept Paediat, NL-3000 CB Rotterdam, Netherlands

[2] Leiden Univ, Med Ctr, Dept Paediat, Leiden, Netherlands

[3] Emma Childrens Hosp, Acad Med Ctr, Jan van Breemen Inst, Dept Paediat, Amsterdam, Netherlands

[4] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Paediat, NL-9713 AV Groningen, Netherlands

[5] Radboud Univ Nijmegen, Med Ctr, Dept Paediat, NL-6525 ED Nijmegen, Netherlands

[6] Hagaziekenhuis Juliana Childrens Hosp, Dept Paediat, The Hague, Netherlands

[7] Utrecht MC Wilhelmina Childrens Hosp, Dept Paediat, Utrecht, Netherlands

[8] Univ Limburg, Acad Hosp Maastricht, Dept Internal Med, Rheumatol Subdiv, Maastricht, Netherlands

来源：

JOURNAL OF RHEUMATOLOGY | 2010年 / 37卷 / 03期

关键词：

JUVENILE IDIOPATHIC ARTHRITIS; ANTIRHEUMATIC AGENTS; TUMOR NECROSIS FACTOR-alpha; DRUG ADMINISTRATION SCHEDULE; TREATMENT OUTCOME; ARTHRITIS; RHEUMATOID-ARTHRITIS; EFFICACY; CHILDREN; THERAPY; SAFETY;

D O I：

10.3899/jrheum.090550

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. To evaluate response in patients with juvenile idiopathic arthritis (JIA) who failed to meet response criteria after 3 months of etanercept treatment. Methods. This was a prospective ongoing Multicenter observational study of all Dutch patients with JIA using etanercept. Response according to American College of Rheumatology Pediatric 30 criteria was assessed at study start and at 3 and 15 months. Results. In total we studied 179 patients of median age 5.8 years at disease onset; 70% were female. Thirty-four patients did not respond after 3 months, of which 20 continued etanercept and 11 achieved response thereafter. Conclusion. The delayed clinically relevant response in a substantial proportion of patients who initially did not respond justifies the consideration of continuing therapy to at least 6 months. (First Release Jan 15 2010; J Rheumatol 20 10;37:665-7 doi: 10.3899/jrheum.090550)

引用

页码：665 / 667

页数：3

共 50 条

[41] Etanercept in juvenile idiopathic arthritis: Who will benefit?
MH Otten
FHM Prince
W Armbrust
R ten Cate
EPAH Hoppenreijs
M Twilt
Y Koopman-Keemink
SL Gorter
KM Dolman
JF Swart
JM van den Berg
NM Wulffraat
MAJ van Rossum
LWA van Suijlekom-Smit
Pediatric Rheumatology, 9 (Suppl 1)
[42] Efficacy of etanercept in the treatment of juvenile idiopathic arthritis
de Inocencio Arocena, J.
Merino Munoz, R.
Alvarez Madrid, C.
Garcia-Consuegra Molina, J.
ANALES DE PEDIATRIA, 2009, 70 (04): : 354 - 361
[43] Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis
Berard, Roberta A.
Laxer, Ronald M.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (11) : 1623 - 1630
[44] Challenges in the management of juvenile idiopathic arthritis with etanercept
Pain, Clare E.
McCann, Liza J.
BIOLOGICS-TARGETS & THERAPY, 2009, 3 : 127 - 139
[45] Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept
Katsicas, MM
Russo, RAG
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2005, 23 (04) : 545 - 548
[46] Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab
María M. Katsicas
Ricardo A. G. Russo
Clinical Rheumatology, 2009, 28 : 985 - 988
[47] Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and infliximab
Katsicas, M. M.
Russo, R. A.
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 551 - 552
[48] Etanercept in patients with juvenile idiopathic arthritis: Results of a retrospective multicenter registry
Calvo, I.
Lopez, B.
Merino, R.
Garcia-Consuegra, J.
Moreno, P.
Lacruz, L.
Bravos, B.
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 440 - 440
[49] Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab
Katsicas, Maria M.
Russo, Ricardo A. G.
CLINICAL RHEUMATOLOGY, 2009, 28 (08) : 985 - 988
[50] Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis
Remesal, A.
Casado, R.
Merino, R.
De Inocencio, J.
Garcia-Consuegra, J.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (02) : 420 - 420

← 1 2 3 4 5 →